Drug Trial Radar · NCT06362759
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
143
Actual
Start
May 15, 2024
Primary completion
Mar 6, 2025
Study completion Dec 4, 2025
Sponsor
- Lead sponsor
- Tourmaline Bio, Inc., a Novartis CompanyIndustry
- Sponsor type
- Industry
- First posted
- Apr 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.
Conditions
- Chronic Kidney Diseases
- Chronic Kidney Insufficiency
- Chronic Renal Diseases
- Chronic Renal Insufficiency
- Kidney Insufficiency, Chronic
- C-Reactive Protein
- High Sensitivity C-Reactive Protein
- Hs-CRP
- hsCRP
Interventions
TOUR006 - 50 MGDrug
TOUR006 50 MG
TOUR006 - 25 MGDrug
TOUR006 25 MG
TOUR006 - 15 MGDrug
TOUR006 15 MG
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-Averaged Percent Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Through Day 90Time frame: Baseline through 90 days. Baseline is defined as the average of the last two available visits prior to study treatment administration.
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Site - 0101
Birmingham, Alabama
Site - 0135
Huntsville, Alabama
Site - 0145
Huntsville, Alabama
Site - 0104
Phoenix, Arizona
Site - 0125
San Dimas, California
Site - 0112
Valencia, California
Site - 0128
Valencia, California
Site - 0136
Stamford, Connecticut
Site - 0113
Greenacres City, Florida
Site - 0149
Pembroke Pines, Florida
Site - 0144
Plantation, Florida
Site - 0119
Port Orange, Florida
Site - 0151
Tampa, Florida
Site - 0122
Savannah, Georgia
Site - 0106
Chicago, Illinois
Site - 0115
Morton, Illinois
Site - 0114
Council Bluffs, Iowa
Site - 0129
Metairie, Louisiana
Site - 0123
Las Vegas, Nevada
Site - 0130
Middletown, New York
Site - 0110
Charlotte, North Carolina
Site - 0117
Fargo, North Dakota
Site - 0120
Cincinnati, Ohio
Site - 0127
Marion, Ohio
Site - 0132
Bethlehem, Pennsylvania
Site - 0126
Providence, Rhode Island
Site - 0102
Fort Mill, South Carolina
Site - 0103
Greenville, South Carolina
Site - 0108
Knoxville, Tennessee
Site - 0148
Greenville, Texas
Site - 0105
Houston, Texas
Site - 0111
Lampasas, Texas
Site - 0150
McKinney, Texas
Site - 0107
San Antonio, Texas
Site - 0141
San Antonio, Texas
Site - 0109
Manassas, Virginia
Site - 0147
Morgantown, West Virginia
Site - 0134
Kenosha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.